1. Scrip
  2. >>Business

Serum Institute Awaiting Gavi Push For $2 Pneumococcal Vaccine

Pricing Comes Close To MSF’s $5 A Course Target

 
• By Vibha Ravi

Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal conjugate vaccine for immunization programs across developing countries. Its 10-valent vaccine, versus GSK’s 11-valent and Pfizer’s 13-valent vaccines, is 30% cheaper.

Vaccination
Serum First Indian Company To Develop Pneumococcal Vaccine • Source: Shutterstock

Serum Institute of India Ltd., a global producer of vaccines, hopes to hear from Gavi, the vaccine alliance, by May this year on whether its $2 alternative to existing pneumococcal conjugate vaccines (PCV) which cost $3 per dose, will be considered for inclusion in its immunization programs.

“We have submitted everything required and between one to three months, we should come to know if we will get approval,” said Serum executive director Rajeev Dhere

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.